Trade Summary

4 days ago, Kumar Neil, serving as Chief Executive Officer at BridgeBio Pharma, Inc. (BBIO), sold 44,980 shares at $82.86 per share, for a total transaction value of $3,727,250.87. Following this transaction, Kumar Neil now holds 505,686 shares of BBIO.

This sale represents a 8.17% decrease in Kumar Neil's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, August 18, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, August 20, 2026 at 4:31 PM ET, 2 days after the trade was made.

BridgeBio Pharma, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.